It is a prospective, controlled, single-center, non-randomized, observational study. From September 2019 to December 2020, the study plans to prospectively include 400 patients aged 18 to 90 years. Every patients will undergo an echocardiographic examination with assessment diastolic dysfunction of the left ventricle, and registration of an electrocardiogram using a single lead ECG monitor CardioQvark (in I standard lead) for 3 minutes. All patients will be divided into 2 main groups: with diastolic dysfunction of the left ventricle, confirmed by the results of the echocardiography and without. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform. The result of this study will be the identification of ECG parameters that will correlate with LV diastolic dysfunction.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
determination of sensitivity of LV DD using a single-channel ECG monitor CardioQvark
Timeframe: through study completion, an average of 2 years
determination of specificity of LV DD using a single-channel ECG monitor CardioQvark
Timeframe: through study completion, an average of 2 years
determination of prognostic value of positive and negative results of LV DD using a single-channel ECG monitor CardioQvark
Timeframe: through study completion, an average of 2 years
determination of likelihood ratio of LV DD using a single-channel ECG monitor CardioQvark
Timeframe: through study completion, an average of 2 years
determination of area under ROC - curve of LV DD using a single-channel ECG monitor CardioQvark
Timeframe: through study completion, an average of 2 years
determination of correlation coefficient of LV DD using a single-channel ECG monitor CardioQvark
Timeframe: through study completion, an average of 2 years